01873.HK
Viva Biotech Holdings
HKSE · Healthcare · Biotechnology · CN
HKD 1.34
−2.20%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 3.7B | 1.7B | 2.0B | 2.2B | 2.4B |
| Cost of Revenue | 2.4B | 1.1B | 1.3B | 1.4B | 1.6B |
| Gross Profit | 1.3B | 655.6M | 687.4M | 738.4M | 815.7M |
| Operating Expenses | |||||
| R&D Expense | 201.9M | 100.5M | 88.0M | 128.0M | 135.8M |
| SG&A Expense | 719.4M | 361.9M | 364.1M | 409.7M | 404.5M |
| General & Admin Expense | 397.5M | 262.8M | 251.9M | 277.1M | 273.6M |
| Selling & Marketing Expense | 155.8M | 101.1M | 112.2M | 132.5M | 130.8M |
| Other Expenses | 5.6M | — | 5.6M | 8.1M | 6.0M |
| Total Operating Expenses | 926.9M | 462.3M | 457.7M | 545.7M | 546.3M |
| Cost and Expenses | 3.3B | 1.5B | 1.8B | 2.0B | 2.1B |
| Operating Income (EBIT) | 413.9M | 193.3M | 229.7M | 192.7M | 269.3M |
| Non-Operating | |||||
| Interest Income | 38.9M | 16.5M | 20.5M | 27.4M | 21.6M |
| Interest Expense | 53.8M | 36.5M | 53.9M | 176.6M | 184.7M |
| Net Interest Income | (37.5M) | (20.1M) | (33.4M) | (149.2M) | (163.1M) |
| Other Non-Op Income/Expense | 122.3M | 124.8M | 66.0M | (248.6M) | (728.5M) |
| Non-Operating Income (excl Interest) | (4.7M) | — | — | — | 3.4M |
| EBT (Pre-Tax Income) | 536.3M | 318.0M | 295.7M | (56.0M) | (459.2M) |
| Income Tax Expense | 89.8M | 48.7M | 73.7M | 43.8M | 45.1M |
| Bottom Line | |||||
| Net Income | 349.2M | 219.8M | 167.3M | (116.1M) | (528.5M) |
| Earnings from Cont. Ops | 446.5M | 269.3M | 222.0M | (99.8M) | (504.2M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 349.2M | 219.8M | 167.3M | (116.1M) | (528.5M) |
| Per Share | |||||
| Basic EPS | HK$0.16 | HK$0.09 | HK$0.08 | (HK$0.06) | (HK$0.28) |
| Diluted EPS | HK$0.15 | HK$0.09 | HK$0.06 | (HK$0.06) | (HK$0.28) |
| Revenue Per Share | HK$1.77 | HK$0.74 | HK$0.93 | HK$1.11 | HK$1.26 |
| Shares | |||||
| Basic Shares Outstanding | 2.1B | 2.3B | 2.1B | 1.9B | 1.9B |
| Diluted Shares Outstanding | 2.4B | 2.3B | 2.9B | 2.0B | 1.9B |
| Profitability Metrics | |||||
| EBITDA | 809.5M | 385.4M | 428.0M | 391.0M | 436.4M |
| D&A | 390.9M | 192.1M | 198.3M | 198.3M | 170.4M |
| EBIT | 418.6M | 193.3M | 229.7M | 192.7M | 266.0M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026